FindTrial
Sign In

Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer

Evaluation of Anticancer Effect of Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03645187
Enrollment
50
Registered
2018-08-24
Start date
2018-08-01
Completion date
2025-12-31
Last updated
2021-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer Stage

Brief summary

The study aimed at evaluation of anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer

Detailed description

The primary aim of the study is to evaluate the anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer

Interventions

DRUGFOLFERI

FOLFERI regimen

DRUGFolferi and celecoxib

Folferi regimen and celecoxib

Sponsors

Sherief Abd-Elsalam
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* advanced colorectal cancer

Exclusion criteria

* cerebral metastases * other malignancy * H pylori infection * thromboembolism

Design outcomes

Primary

MeasureTime frameDescription
number of patients with improved radiology6 monthsnumber of patients with improved radiology

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, MD
sheriefabdelsalam@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026